DUSP1 and COVID-19: Identifying elements contributing to the dysregulation of these pro-inflammatory cytokines during COVID-19, such as reduced expression of DUSP1 and DUSP5, may pave the way for therapeutic intervention to control the level of these cytokines and hence their pathological implications.